25 results about "Meglumine" patented technology

The invention relates to the field of agricultural bactericides, in particular to a suspending agent containing fenaminstrobin and validamycin A and application of the suspending agent. The bactericidal composition comprises a suspending agent containing fenaminstrobin and validamycin A, an active component, a stabilizer, an auxiliary agent and water, the active component accounts for 1-70% of the mass of the preparation, and the stabilizer accounts for 0.1-10% of the mass of the preparation; wherein the active ingredients are fenaminstrobin and validamycin A, and the stabilizer is meglumine (N-methyl-D-glucosamine). The suspending agent prepared by the technical scheme of the invention effectively inhibits the increase of the particle size of a sample in the thermal storage process of a preparation, effectively improves the suspension rate of fenaminstrobin after the thermal storage of the preparation, improves the utilization rate of a pesticide, and ensures the normal exertion of the efficacy of the pesticide at the same time. Meanwhile, the quality of the active components of the stabilizer-containing bactericide is stable within the shelf life, the addition of the stabilizer does not cause the decomposition of the active components, and the preparation does not have obvious physical or chemical change.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

A composition for carbon dioxide (CO2) capture includes 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, or combinations thereof. A process of CO2 capture includes mixing a CO2-containing gas with the composition. A system includes a component for receiving a gas and the composition, which absorbs CO2 from the gas. A further composition includes a first amine solvent selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine and a second amine solvent independently selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, ethyl diethanolamine, dimethylethanolamine, piperidine, 2-amino-2-methyl-1-propanol, and monoethanolamine. A further process includes reacting CO2 with an amine selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The invention provides a crystal form of a compound HIF-117 salt as well as a preparation method and application of the crystal form, and the crystal form is any one or more of the following crystal forms: a hydrochloride crystal form A, a sulfate crystal form B, a 1, 2-ethanedisulfonate crystal form C1, 1, 2-ethanedisulfonate crystal form C2, 1, 2-ethanedisulfonate crystal form C3 and 1, 2-ethanedisulfonate crystal form C4. The crystal form 1, 2-ethanedisulfonate crystal form C2, p-toluenesulfonate crystal form D, mesylate crystal form E1, mesylate crystal form E2, hydrobromide crystal form F1, hydrobromide crystal form F2, sodium salt crystal form G, sylvite crystal form H1, sylvite crystal form H2, calcium salt crystal form I, magnesium salt crystal form J, choline salt crystal form K, lysine salt crystal form L, ammonium salt crystal form M, meglumine salt crystal form N, betaine salt crystal form O1, betaine salt crystal form O2 and diethylamine salt crystal form P1, the invention relates to a diethylamine salt crystal form P1, a diethylamine salt crystal form P2, a diethylamine salt crystal form P3, a diethylamine salt crystal form P4, a diethylamine salt crystal form P5, a tromethamine salt crystal form Q1, a tromethamine salt crystal form Q2 and a tromethamine salt crystal form Q3. The compound has good stability, and has important value for development and production of medicines and preparations.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The invention belongs to the technical field of capsule preparations, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is prepared from hydroxypropyl starch, carrageenan, plantain seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and glue preparation, vacuum degassing, soft capsule forming and drying. Through the innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance and can adapt to transportation and storage at extreme temperature; meanwhile, the product is mainly prepared from plant source raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and the market acceptability are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The present invention relates to a liquid pharmaceutical composition comprising (i) totally dissolved tretinoin or a pharmaceutically acceptable isomer thereof; (ii) d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS); (iii) a pH-modifying agent selected in the group consisting of meglumine, potassium hydroxide (KOH), sodium hydroxide (NaOH), sodium acetate (anhydrous, trihydrate, and mixtures thereof), potassium acetate (anhydrous, trihydrate, and mixtures thereof), di-potassium hydrogenophosphate, di-sodium hydrogenophosphate, tri-sodium phosphate, tri-potassium phosphate, and mixtures thereof; and (iv) water. The present invention also relates to the medical uses of such a composition.

The application discloses a super-long chain glucose amide nonionic surfactant and a synthesis method thereof. The hydrophobic tail chain of the surfactant is derived from plant-based fatty acids such as oleic acid, erucic acid or nervonic acid, and the hydrophilic head group is derived from glucose derivatives such as meglumine and glycolglucamine. With oleic acid, erucic acid and nervonic acid in rapeseed by-product as hydrophobic tail chain raw material, glucose derivatives meglumine and glycolglucamine as hydrophilic head group raw material, methanol, ethanol, ethylene glycol or propylene glycol (single solvent or binary mixed solvent) as solvent, and DMAP or NaF as catalyst, a kind of bio-based surfactant is obtained. The super-long chain glucose amide nonionic surfactant is prepared by selective amination reaction, the hydroxyl group in the glucose amine molecule does not need to be protected complicatedly, the reaction temperature is close to room temperature, the operation is simple, and the purification process only needs a simple industrial crystallization method, which is suitable for industrial production.

A method produces an aqueous liquid preparation for magnetic resonance contrast that contains a complex of a lanthanide and a macrocyclic chelate together with free chelate. A solution of the macrocyclic chelate in water is prepared, lanthanide and meglumine are added, and complex formation proceeds in the presence of meglumine at a pH between 6.5 and 8.0 with lanthanide in molar excess over meglumine and meglumine in molar excess over the chelate. The pH is then reduced to a target value below 5.0 by incremental addition of an acid such as further chelate, optionally followed by addition of a fixed chelate amount. The pH is subsequently raised above 6.5 with meglumine and the solution is diluted to a final volume, providing an industrial-scale single-vessel process that yields a preparation containing a defined low amount of free lanthanide.

The invention belongs to the technical field of organic synthesis, and particularly relates to a synthetic method of meglumine. The method comprises the following steps: 1) dissolving glucose and methylamine in water to prepare a reaction solution; 2) adding a catalyst into the reaction liquid for reaction; and 3) after the reaction is finished, filtering and separating the catalyst, and carrying out post-treatment on the reaction liquid to obtain the meglumine. On the basis of mature reductive amination reaction, a green and environment-friendly water phase system and an efficient heterogeneous catalysis path are selected, high efficiency and high selectivity of product conversion are achieved by means of the structural advantage of the hierarchical porous Ni / SiO2-Hier catalyst and the requirement high matching capacity of a reaction system, and the method has the synthesis advantages of being green and efficient.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a celecoxib tablet and a preparation method thereof.The celecoxib tablet is composed of celecoxib, lactose-microcrystalline cellulose compounded according to a specific proportion, polyvinylpolypyrrolidone-carboxymethyl starch sodium, a lubricant and a solubilizing stabilizer. Wherein the solubilizing stabilizer is beta-cyclodextrin, sodium stearoyl lactylate and meglumine. The preparation method comprises the steps of pretreatment of the celecoxib and the solubilizing stabilizer, step-by-step granulation, drying and size stabilization, and total mixing and tabletting. Through the synergistic effect of the compound solubilizing stabilizer and the wet grinding process and in combination with the preparation method of step-by-step mixing granulation, the content uniformity, the dissolution performance and the storage stability of the prepared celecoxib tablet are remarkably improved, and the preparation process is simple and easy to operate and suitable for industrial large-scale production.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

The present application belongs to the technical field of capsule preparation, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is composed of hydroxypropyl starch, carrageenan, psyllium seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and gel preparation, vacuum degassing, soft capsule forming and drying. Through innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance, can adapt to transportation and storage under extreme temperature, and is mainly made of plant-derived raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and market acceptance are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The present application relates to a kind of carboprost tromethamine injection and its preparation method.The injection uses meglumine as pH regulator, not only stable to CO2 in environment, and it is beneficial to improve the stability of carboprost tromethamine;At the same time, pre-charged needle injection is also avoided the operation of ampoule sealing, so that the prepared carboprost tromethamine injection can be stored at 2~20 ℃, storage and transportation and clinical use are more convenient.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to cefixime granules and a preparation method thereof. The cefixime granules provided by the invention are prepared from cefixime, a dissolution-promoting and stability-maintaining agent and pharmaceutically acceptable auxiliary materials, wherein the dissolution-promoting and stability-maintaining agent is a combination of sodium caprylate and meglumine; meanwhile, the dissolution-promoting stability-maintaining agent and the cefixime are subjected to a specific pretreatment process, and then the cefixime particles are prepared through a wet granulation process. According to the technical scheme, the dissolution performance and the stability of the cefixime granules are synergistically optimized, and the preparation process is simple, convenient and controllable, does not need to depend on a special high-energy-consumption process, has relatively high industrial feasibility and is beneficial to large-scale production and market promotion.

The invention discloses a preparation method of gadotec acid meglumine. The gadotec acid meglumine is prepared by taking DOTA, gadolinium oxide and meglumine as raw materials. Wherein the related substances in the DOTA meet the following conditions in percentage by mass: less than or equal to 0.05% of impurity RM, and / or less than or equal to 0.05% of impurity P01, less than or equal to 0.05% of impurity P02, less than or equal to 0.05% of impurity P03, less than or equal to 0.05% of impurity P04 and less than or equal to 0.5% of total impurities. The invention also relates to the bulk drug prepared by the preparation method and a high performance liquid chromatography detection method thereof. On the basis of deep research, according to consideration factors such as the importance degree of each quality index and / or the difficulty degree of removing one or some impurities, key process conditions or parameters for preparing gadadotec acid meglumine are finally found out and determined; product quality management and / or control of the production source and even the whole process of the gadadotec acid meglumine bulk drug are / is really realized and strengthened, and the medication safety of vast patients is better guaranteed.

The application relates to the technical field of medicines, in particular to an icotinamide tablet of icotinib and a preparation method thereof; the icotinamide tablet of icotinib comprises the following components: icotinamide, an amphiphilic carrier, a microenvironment regulator and pharmaceutically acceptable adjuvants, wherein the mass ratio of the icotinamide, the amphiphilic carrier and the microenvironment regulator is 1:(1-3):(0.5-1.5), the amphiphilic carrier is Soluplus, and the microenvironment regulator is meglumine; the application discloses an icotinamide tablet of icotinib and a preparation method thereof; the three components of icotinamide, the amphiphilic carrier Soluplus and the microenvironment regulator meglumine are ground together, the solubility and the dissolution of the medicine in a high-calcium medium can be effectively improved, the postprandial bioavailability is increased, and the stability is good.

The present invention relates to a smokeless article for oral delivery comprising a pouch enclosing an oral nicotine delivery (OND) formulation, the OND formulation comprising at least two pH regulators selected from the list of sodium carbonate, sodium hydroxide, calcium lactate, sodium phosphate dibasic, sodium citrate, meglumine, ammonia, ammonium carbonate, and calcium carbonate. A method of manufacturing the article and kits comprising the article are also described.

The invention provides a high performance liquid chromatography analysis method of chlorbuconazole meglumine, and belongs to the technical field of pharmaceutical analys.The analysis method comprises the steps that chlorbuconazole meglumine is taken to be prepared into a test solution, then a glacial acetic acid aqueous solution serves as a mobile phase A, acetonitrile serves as a mobile phase B, reversed-phase high performance liquid chromatography detection is conducted through gradient elution, and the content of chlorbuconazole meglumine is obtained. The method is used for detecting impurities in meglumine chlorzolate. The analysis method disclosed by the invention can be used for analyzing the meglumine chlorzolate and eliminating interference factors, is simple, efficient, reliable and accurate to operate, and is an effective means for providing research work of the meglumine chlorzolate and industrial production management in a production process.

The invention discloses ambroxol hydrochloride syrup and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. The ambroxol hydrochloride syrup comprises ambroxol hydrochloride, a stabilizing cosolvent, a sweetening agent, a preservative, a pH regulator, essence and a solvent. Wherein the stable cosolvent is a composition of propylene glycol, meglumine and propylene carbonate, and the sweetening agent is a composition of cane sugar and a functional sweetening agent. The preparation process comprises the steps of low-temperature pretreatment of the main drug and the stable cosolvent, dissolution and mixing of the auxiliary materials, pH adjustment and essence addition, constant-volume filtration, encapsulation and the like. Through the synergistic effect of a composite stable cosolvent system and a specific preparation process, the storage stability of ambroxol hydrochloride is remarkably improved, meanwhile, the taste of the preparation is optimized, the preparation is wide in applicable crowd, the preparation process is simple and controllable, and good clinical application value and industrialization prospects are achieved.

The invention relates to the technical field of preparation of pharmaceutical preparations, and particularly discloses a meloxicam injection and a preparation method thereof. The preparation method comprises the following steps: mixing tetrahydrofuran polyglycol ether, poloxamer and water for injection, which accounts for 35-45% of the formula amount, so as to obtain a blank micelle solution; the preparation method comprises the following steps: mixing meglumine, meloxicam and injection water accounting for 15-25% of the formula amount to obtain a medicine-containing solution; mixing the blank micelle solution, the medicine-containing solution and glycine, adding sodium chloride and sodium hydroxide, then adding the balance of water for injection, filling and sterilizing to obtain the meloxicam injection. The stable micelle structure is prepared by limiting the specific feeding sequence and controlling the water adding amount of the blank micelle solution, so that the stability of the blank micelle after drug loading is ensured. The meloxicam injection prepared by the invention can be stably stored for more than 2 years at the temperature of below 30 DEG C.

The application provides a preparation method of sildenafil citrate and telmisartan sustained-release tablets, which comprises the following steps: obtaining a tablet core by wet granulation, drying, total mixing and tabletting of sildenafil citrate and auxiliary materials; adding telmisartan into an aqueous solution of sodium hydroxide and meglumine to prepare sodium telmisartan by granulation; forming a fast-release coating slurry by mixing the sodium telmisartan and coating materials; and coating the tablet core in a coating machine by using the prepared fast-release coating slurry to obtain the sildenafil citrate and telmisartan sustained-release tablets. The application adopts a unique microporous penetration controlled-release technology. When the drug is taken, water molecules penetrate into the tablet core through the membrane, the drug component is dissolved to generate osmotic pressure, and the drug is slowly and constantly released at a zero-order or near zero-order rate under the osmotic pressure in the membrane, thereby prolonging the sustained-release time of sildenafil citrate.

The invention belongs to the technical field of pharmaceutical preparations, and discloses preparation of doxorubicin and immunomodulator co-loaded liposome and synergistic anti-tumor application of the doxorubicin and immunomodulator co-loaded liposome. The doxorubicin and immunomodulator co-loaded liposome disclosed by the invention is prepared from doxorubicin hydrochloride, icariin, phospholipid, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000, cholesterol, alpha-tocopherol, arginine, meglumine, ammonium sulfate, a buffer solution and water for injection. The co-loaded liposome disclosed by the invention can be further prepared into freeze-dried powder containing a freeze-drying protective additive, and the redissolution stability is excellent. The co-carrier liposome is good in stability, can play a synergistic anti-tumor effect of chemotherapy killing effect of doxorubicin and immunoregulation effect of icariin, can be used for anti-tumor medicine preparations, and provides an efficient preparation scheme for malignant tumor treatment.

The present application relates to a plurality of crystal forms of S-indobufen salt, preparation method and use, the plurality of crystal forms specifically relates to 2 potassium salt crystal forms, 5 calcium salt crystal forms, 3 magnesium salt crystal forms, 4 ammonium salt crystal forms, 1 choline salt crystal form Type A, 4 meglumine salt crystal forms, 4 lysine salt crystal forms, 3 betaine salt crystal forms, 1 diethylamine salt crystal form, 5 tromethamine salt crystal forms, 2 proline co-crystals, 1 urea co-crystal and 1 cetylamine salt.The S-indobufen salt has excellent solubility, compressibility and stability, low moisture absorption and adhesion, very uniform particle size distribution, and unique advantages in preparation and application.